Cargando…

Pegylated Liposomal Doxorubicin (Caelyx(®)) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial

Background: Adjuvant chemotherapy for Luminal B-like breast cancers usually includes anthracycline-based regimens. However, some patients are reluctant to receive chemotherapy because of side-effects, especially alopecia, and ask for a “less intensive” or personalized approach. Patients and methods:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dellapasqua, Silvia, Trillo Aliaga, Pamela, Munzone, Elisabetta, Bagnardi, Vincenzo, Pagan, Eleonora, Montagna, Emilia, Cancello, Giuseppe, Ghisini, Raffaella, Sangalli, Claudia, Negri, Mara, Mazza, Manuelita, Iorfida, Monica, Cardillo, Anna, Sciandivasci, Angela, Bianco, Nadia, De Maio, Ana Paula, Milano, Monica, Campennì, Giuseppe Maria, Sansonno, Loredana, Viale, Giuseppe, Morra, Anna, Leonardi, Maria Cristina, Galimberti, Viviana, Veronesi, Paolo, Colleoni, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700739/ https://www.ncbi.nlm.nih.gov/pubmed/34940072 http://dx.doi.org/10.3390/curroncol28060433

Ejemplares similares

Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines
por: Munzone, Elisabetta, et al.
Publicado: (2019)

Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy
por: Montagna, Emilia, et al.
Publicado: (2020)

Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials
por: Munzone, E., et al.
Publicado: (2021)

Management of breast cancer patients during the peak of the COVID 19 pandemic
por: Montagna, E., et al.
Publicado: (2021)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
por: Iorfida, Monica, et al.
Publicado: (2020)

Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer
por: Torrisi, R, et al.
Publicado: (2007)

Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx(®)) as Pressurized Intraperitoneal Aerosol Chemotherapy
por: Robella, Manuela, et al.
Publicado: (2019)

Outcome and clinico-biological characteristics of advanced breast cancer patients with surgically resected brain metastases: a multidisciplinary approach
por: Munzone, Elisabetta, et al.
Publicado: (2013)

The added value of whole-body magnetic resonance imaging in the management of patients with advanced breast cancer
por: Zugni, Fabio, et al.
Publicado: (2018)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
por: Maisonneuve, Patrick, et al.
Publicado: (2014)

Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer
por: Montagna, E, et al.
Publicado: (2008)

High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours
por: Koukourakis, M I, et al.
Publicado: (2000)

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
por: Orlando, Laura, et al.
Publicado: (2006)

Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study
por: Pece, Salvatore, et al.
Publicado: (2019)

Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis
por: Bianco, Nadia, et al.
Publicado: (2021)

(99m)Tc-labelled Stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours
por: Laverman, P, et al.
Publicado: (2002)

Reply: (99m)Tc-labelled Stealth liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours
por: Koukourakis, M I
Publicado: (2002)

Optimal management of luminal breast cancer: how much endocrine therapy is long enough?
por: Munzone, Elisabetta, et al.
Publicado: (2018)

Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
por: Giugliano, Federica, et al.
Publicado: (2023)

Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx™) in human osteosarcoma xenografts
por: Eikenes, L, et al.
Publicado: (2005)

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity
por: Torrisi, R, et al.
Publicado: (2008)

Reply to Comments on: “Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp cooling system in early breast cancer patients treated with anthracyclines.”
por: Munzone, Elisabetta, et al.
Publicado: (2019)

Diagnostic performance of image-guided vacuum-assisted breast biopsy after neoadjuvant therapy for breast cancer: prospective pilot study
por: Rossi, Elisabetta M C, et al.
Publicado: (2022)

Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center
por: Nicosia, Luca, et al.
Publicado: (2022)

Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx(®)) or vincristine
por: Verreault, Maite, et al.
Publicado: (2011)

A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx (®) in advanced breast cancer
por: Li, Yinjuan, et al.
Publicado: (2022)

Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis
por: Conforti, Fabio, et al.
Publicado: (2021)

Properties of Two Enterovirus Antibodies that are Utilized in Diabetes Research
por: Maccari, Giuseppe, et al.
Publicado: (2016)

Mutations targeting the coagulation pathway are enriched in brain metastases
por: Richichi, Cristina, et al.
Publicado: (2017)

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
por: Ferrando, Lorenzo, et al.
Publicado: (2023)

Expression of tumor-associated antigens in breast cancer subtypes
por: Curigliano, Giuseppe, et al.
Publicado: (2019)

Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial
por: Gentilini, Oreste Davide, et al.
Publicado: (2023)

Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence
por: Conforti, Fabio, et al.
Publicado: (2019)

Impact of autoimmune diseases on outcome of patients with early breast cancer
por: Criscitiello, Carmen, et al.
Publicado: (2016)

Breast Adjuvant Radiotherapy Amid the COVID-19 Crisis in a Hub Cancer Center, Lombardy, Italy
por: Leonardi, Maria Cristina, et al.
Publicado: (2021)

Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer
por: Cancello, Giuseppe, et al.
Publicado: (2008)

Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group
por: Licata, Luca, et al.
Publicado: (2023)

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
por: Dowsett, Mitch, et al.
Publicado: (2018)

Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials()
por: Pala, Laura, et al.
Publicado: (2023)

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
por: Munzone, Elisabetta, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_kmak28v4oe9gnq78i7fgq9v4ge